ABEO
NASDAQ · Biotechnology
Abeona Therapeutics Inc
$5.13
+0.23 (+4.69%)
Income Statement
| FY 2025 | FY 2024 | FY 2023 | |
|---|---|---|---|
| Revenue | 42.03M | 39.71M | 32.89M |
| Net Income | -4,956,318 | -4,431,314 | -3,676,832 |
| EPS | — | — | — |
| Profit Margin | -11.8% | -11.2% | -11.2% |
| Rev Growth | +0.4% | +12.5% | +7.0% |
Balance Sheet
| FY 2025 | FY 2024 | FY 2023 | |
|---|---|---|---|
| Total Debt | 40.65M | 47.63M | 42.47M |
| Total Equity | 214.91M | 217.43M | 201.44M |
| D/E Ratio | 0.19 | 0.22 | 0.21 |
Cash Flow
| FY 2025 | FY 2024 | FY 2023 | |
|---|---|---|---|
| EBITDA | -5,373,900 | -4,969,444 | -4,544,257 |
| Free Cash Flow | -5,460,500 | -4,447,710 | -3,857,678 |